GlassScriptPhysician profile
Sirna Musa
NPI 1376034660
$1,253.37
in general payments reported to CMS, 2019-2025
11 companies · $215 in 2025
The $215 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $245 · 2022: $28.90 · 2023: $491 · 2024: $273 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $979.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $443.94 | 2023-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $157.72 | 2022-2024 | Pifeltro, Delstrigo |
| Novo Nordisk INC | $121.77 | 2021-2022 | |
| Viiv Healthcare Company | $105.24 | 2023-2025 | Dovato, Cabenuva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.43 | 2021 | |
| Theratechnologies INC. | $96.89 | 2023 | Trogarzo |
| Janssen Products, LP | $88.78 | 2023 | Symtuza |
| Shionogi INC | $86.18 | 2024 | Fetroja |
| Abbott Laboratories | $19.20 | 2021 | |
| Janssen Biotech, INC. | $18.13 | 2023 | Symtuza |
| Lilly USA, LLC | $12.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sirna Musa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.